Loading…
Loading…
Phase 3 DeLLphi-305 Study Delivered Highly Significant and Clinically Meaningful Overall Survival Benefit Versus Durvalumab Alone Study Also Met Secondary Progression-Free Survival and Objective Response Rate Endpoints THOUSAND OAKS, Calif., Sept. 8, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced landmark results from the Phase 3 DeLLphi-305 study, which met its primary endpoint at a pre-specified interim analysis, demonstrating a statistically significant and clinically meaningful improvement in overall survival with IMDELLTRA® (tarlatamab-dlle) in combination with AstraZeneca's Imfinzi® (durvalumab) compared to durvalumab alone.
New Program Introduces Flexible Rewards, Status Recognition, Milestone Benefits and More Ways for Guests to Unlock Meaningful Value MIAMI, Sept. 1, 2026 /PRNewswire/ -- Carnival Cruise Line launched Carnival Rewards today, a first-of-its-kind loyalty program in the cruise industry that gives guests more ways to earn rewards, achieve status and be recognized in ways that matter most to them.
BlackRock Inc. bought a new position in shares of Lineage, Inc. (NASDAQ: LINE) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 5,260,370 shares of the company's stock, valued at approximately $227,511,000. BlackRock Inc. owned 2.31% of Lineage as of its most recent
BOCA RATON, Fla., Aug. 17, 2026 (GLOBE NEWSWIRE) -- KARMAN LINE ACQUISITION CORP. (the “Company”), a special purpose acquisition company, today announced the pricing of its initial public offering of 20,000,000 units at a price of $10.00 per unit. The units are expected to be listed for trading on the Nasdaq Global Market (“Nasdaq”) under the ticker symbol “XTERU” beginning August 18, 2026. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant of the Company. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share, subject to certain adjustments. Once the securities comprising the units begin separate trading, the Company expects that its Class A ordinary shares and warrants will be listed on Nasdaq under the symbols “XTER” and “XTERW,” respectively. The offering is expected to close on August 19, 2026, subject to customary closing conditions.
Lineage Cell Therapeutics NYSEAMERICAN: LCTX outlined progress across its cell-therapy pipeline during its second-quarter 2026 earnings call, highlighting preclinical advances in corneal disease, Type 1 diabetes and hearing loss programs while Roche and Genentech continue surgical-delivery optimization work for its lead OpRegen program.
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Q2 2026 Earnings Release.
Lineage, Inc. (LINE) Q2 2026 Earnings Call Transcript
Lineage NASDAQ: LINE reported second-quarter results that exceeded its internal expectations and consensus estimates as warehouse occupancy improved and cost-control efforts helped offset continued trade-related volume pressure.